ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

Core Insights - ZyVersa Therapeutics, Inc. is advancing its clinical-stage biopharmaceutical pipeline focused on renal and inflammatory diseases, reporting financial results for Q2 2025 and progress on key milestones [2][3] Financial Performance - As of June 30, 2025, cash on hand was $0.1 million, with a recent financing transaction providing $2.05 million [8] - Research and development expenses decreased by 42.2% to $0.4 million compared to Q2 2024, attributed to lower costs in various areas [9] - General and administrative expenses decreased by 20.1% to $1.6 million compared to Q2 2024, primarily due to reductions in insurance premiums and professional fees [10] - Net losses improved to approximately $2.2 million, a 20% reduction from the net loss of approximately $2.8 million in Q2 2024 [11] Pipeline Developments - The company is developing VAR 200, targeting diabetic kidney disease (DKD), with a Phase 2a trial initiated in Q3 2025 and interim results expected in Q4 2025 [4][5] - IC 100, an inflammasome inhibitor, is progressing towards IND submission, with a preclinical study planned for Q4 2025 [5][6] - The global drug market for kidney disease is projected to grow from $18 billion in 2024 to $30 billion by 2034, while the global biologics market for inflammatory diseases is expected to increase from $105 billion in 2024 to $186 billion by 2034 [4][5] Operational Insights - The first patient in the Phase 2a trial for VAR 200 is expected to be treated in Q3 2025, focusing on safety and efficacy in patients with DKD [4] - The IND-enabling study for IC 100 will evaluate its effects in a diet-induced obesity animal model, with a Phase 1 trial planned for healthy overweight individuals post-IND clearance [6][7] - The company raised approximately $4.05 million year-to-date, indicating ongoing efforts to secure funding for operations and clinical activities [5]